S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
LON:DEST

Destiny Pharma (DEST) Share Price, News & Analysis

GBX 21.25
+2.00 (+10.39%)
(As of 04/19/2024 ET)
Today's Range
19.33
21.50
50-Day Range
17.50
46
52-Week Range
16.50
84
Volume
645,292 shs
Average Volume
417,878 shs
Market Capitalization
£20.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DEST stock logo

About Destiny Pharma Stock (LON:DEST)

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.

DEST Stock Price History

DEST Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Oprah, Ozempic and Us
Holding up half the sky
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
An Instant Crush Over Mashed Potatoes
Destiny Pharma PLC DEST
Destiny Pharma. Share Chat
See More Headlines
Receive DEST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Destiny Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/17/2020
Today
4/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
24
Year Founded
N/A

Profitability

Net Income
£-5,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£135,028.00
Cash Flow
GBX 7.90 per share
Book Value
GBX 14 per share

Miscellaneous

Free Float
N/A
Market Cap
£20.25 million
Optionable
Not Optionable
Beta
0.27
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. William Guy Love (Age 62)
    Founder, Chief Scientific Officer & Director
    Comp: $265k
  • Mr. Shaun Claydon ACA (Age 56)
    CFO, Company Secretary & Director
    Comp: $286k
  • Dr. Debra Barker M.D. (Age 62)
    MSc., Interim CMO & Senior Independent Director
    Comp: $41k
  • Mr. Christopher John Tovey BSc (Age 59)
    CEO & Director

DEST Stock Analysis - Frequently Asked Questions

How have DEST shares performed in 2024?

Destiny Pharma's stock was trading at GBX 70 on January 1st, 2024. Since then, DEST stock has decreased by 69.6% and is now trading at GBX 21.25.
View the best growth stocks for 2024 here
.

How were Destiny Pharma's earnings last quarter?

Destiny Pharma plc (LON:DEST) posted its quarterly earnings data on Thursday, September, 17th. The company reported ($5.50) earnings per share for the quarter.

What other stocks do shareholders of Destiny Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include Dynavax Technologies (DVAX), AFPO.L (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB) and EQTEC (EQT).

How do I buy shares of Destiny Pharma?

Shares of DEST stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:DEST) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners